相关实验视频
Updated: Jun 19, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
12.8K
对外基在心脏代谢终点上的交叉试验,用于心力衰竭与保存的喷射分数
Senthil Selvaraj1, Antoneta Karaj2, Julio A Chirinos3
1Division of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Duke University Medical Center, Durham, North Carolina, USA; Duke Molecular Physiology Institute, Durham, North Carolina, USA; Cardiovascular Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
JACC. Heart failure
|April 17, 2025
概括
乙烯 (KE) 补充剂没有改善心力衰竭的运动耐受性与保存的喷射分数 (HFpEF). 尽管基质使用转移,填充压力降低,但HFpEF患者的峰值氧气消耗和耐力保持不变.
科学领域:
- 心脏病学 心脏病学
- 代谢医学是一种代谢医学.
- 运动生理学 运动生理学
背景情况:
- 运动不耐受是心力衰竭的关键症状之一,心力衰竭的关键症状是保持喷射分数 (HFpEF).
- 乙醇 (KE) 正在被研究为一种潜在的治疗策略,以改善促进HFpEF的代谢途径.
- 了解KE对HFpEF运动能力的影响对于开发新疗法至关重要.
研究的目的:
- 评估急性乙醇 (KE) 补充剂在改善HFpEF患者的运动耐受性方面的疗效.
- 在HFpEF中评估KE在运动期间对心肺呼吸和代谢参数的影响.
主要方法:
- 一个随机,交叉,安慰剂对照试验 (KETO-HFpEF) 涉及20名有症状的HFpEF参与者.
- 主要终点包括在增量运动期间的峰值氧气消耗 (VO2) 和在恒定强度运动期间耗尽的时间.
- 二次评估包括基质利用率,血液动力学参数和估计的左心室填充压力.
主要成果:
- 与安慰剂相比,KE补充剂没有显著改善VO2峰值或运动耐力.
- KE将基质利用转移到碳水化合物之外,这可以通过较低的呼吸交换比率来证明.
- KE降低了非化的脂肪酸,葡萄糖和估计的左心室填充压力 (E / e') 在休息状态下,但这些影响在运动期间减少.
结论:
- 急性KE补充剂不会提高HFpEF患者的运动能力,尽管可以达到症并改变基质代谢.
- 需要进一步的研究来探索替代剂量策略或HFpEF内的不同人群.
- KE对心脏功能和基质使用的影响需要在心血管疾病中继续进行研究.
相关概念视频
01:16Crossover Experiments
Crossover experiments, also called the repeated-measurements design, is a study design in which all experimental units are exposed to all treatments in different periods. Crossover experiments are generally used in psychology, the pharmaceutical industry, agriculture, and medicine.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
Crossover designs are performed even with smaller sample sizes since the samples can act as their controls. These are better than simple randomized trials since patients are exposed to all the treatments.
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...